

# Appendix 3Y

## Change of Director's Interest Notice

*Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.*

Introduced 30/09/01 Amended 01/01/11

<b>Name of entity</b>	<b>BENITEC BIOPHARMA LIMITED</b>
<b>ABN</b>	<b>64 068 943 662</b>

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

**The purpose of this Appendix 3Y is to correct the document provided earlier today where the exercise price was inadvertently shown as \$0.0325 instead of \$0.325 (32.5 cents) in Part 1. The other information remains unchanged.**

<b>Name of Director</b>	<b>KEVIN BUCHI</b>
<b>Date of last notice</b>	<b>18 November 2013</b>

### Part 1 - Change of director's relevant interests in securities

*In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust*

Note: In the case of a company, interests which come within paragraph (i) of the definition of "notifiable interest of a director" should be disclosed in this part.

<b>Direct or indirect interest</b>	<b>Direct and indirect</b>
<b>Nature of indirect interest (including registered holder)</b> Note: Provide details of the circumstances giving rise to the relevant interest.	<b>Nexan Healthcare LLC</b>
<b>Date of change</b>	<b>27 November 2014</b>
<b>No. of securities held prior to change</b>	<b>Direct</b> <b>400,000 Unlisted NED Options exercise price \$0.625 (62.5 cents) expiry 18 May 2018</b>  <b>Indirect</b> <b>615,385 Ordinary shares</b> <b>246,154 Listed Options exercise price \$0.325 (32.5 cents) expiry 18 February 2015</b>
<b>Class</b>	<b>as above</b>

+ See chapter 19 for defined terms.

## Appendix 3Y Change of Director's Interest Notice

<b>Number acquired</b>	<b>Indirect</b> 246,154 shares issued by the exercise of options at \$0.325 (32.5 cents) with an expiry 18 February 2015
<b>Number disposed</b>	nil
<b>Value/Consideration</b> Note: If consideration is non-cash, provide details and estimated valuation	AUD 80,000
<b>No. of securities held after change</b>	<b>Direct</b> 400,000 Unlisted NED Options exercise price \$0.625 (62.5 cents) expiry 18 May 2018  <b>Indirect</b> 861,539 Ordinary shares
<b>Nature of change</b> Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buy-back	246,154 shares issued by the exercise of options at \$0.325 (32.5 cents ) with an expiry 18 February 2015

### Part 2 – Change of director's interests in contracts

Note: In the case of a company, interests which come within paragraph (ii) of the definition of "notifiable interest of a director" should be disclosed in this part.

<b>Detail of contract</b>	<b>Not applicable</b>
<b>Nature of interest</b>	
<b>Name of registered holder (if issued securities)</b>	
<b>Date of change</b>	
<b>No. and class of securities to which interest related prior to change</b> Note: Details are only required for a contract in relation to which the interest has changed	
<b>Interest acquired</b>	
<b>Interest disposed</b>	
<b>Value/Consideration</b> Note: If consideration is non-cash, provide details and an estimated valuation	
<b>Interest after change</b>	

### Part 3 – <sup>+</sup>Closed period

<b>Were the interests in the securities or contracts detailed above traded during a <sup>+</sup>closed period where prior written clearance was required?</b>	No
<b>If so, was prior written clearance provided to allow the trade to proceed during this period?</b>	
<b>If prior written clearance was provided, on what date was this provided?</b>	

+ See chapter 19 for defined terms.